LTRN — Lantern Pharma Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-06-11.
Performance
Technicals
Others in Healthcare
Measured signals that fired on LTRN
| date | signal | measured base rate |
|---|---|---|
| 2026-03-06 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-05-12 | KEYSER D JEFFREY Director | Open-market purchase | 48.5K | 2.06 | 100.0K |
| 2026-05-12 | Schalop Lee Troy Director | Open-market purchase | 48.5K | 2.06 | 100.0K |
| 2025-06-13 | Bios Equity Partners II, LP | Open-market sale | 14.2K | 3.09 | 43.9K |
| 2025-06-13 | BIOS Fund II NT, LP | Open-market sale | 14.2K | 3.09 | 43.9K |
| 2025-06-13 | BIOS Fund II QP, LP | Open-market sale | 14.2K | 3.09 | 43.9K |
| 2025-06-13 | BIOS Fund I QP, LP | Open-market sale | 14.2K | 3.09 | 43.9K |
| 2025-06-13 | Fletcher Aaron G.L. | Open-market sale | 14.2K | 3.09 | 43.9K |
| 2025-06-13 | BIOS Fund I, LP | Open-market sale | 14.2K | 3.09 | 43.9K |
| 2025-06-13 | BIOS Fund II, LP | Open-market sale | 14.2K | 3.09 | 43.9K |
| 2025-06-13 | Bios Equity Partners, LP | Open-market sale | 14.2K | 3.09 | 43.9K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BIOS Capital Management, LP | 1.2M | 864.4K |
| VANGUARD CAPITAL MANAGEMENT LLC | 454.9K | 332.1K |
| CM Management, LLC | 342.5K | 250.0K |
| RENAISSANCE TECHNOLOGIES LLC | 158.9K | 116.0K |
| GEODE CAPITAL MANAGEMENT, LLC | 153.0K | 111.6K |
| Westside Investment Management, Inc. | 68.6K | 50.0K |
| Voss Capital, LP | 68.5K | 50.0K |
| VANGUARD FIDUCIARY TRUST CO | 68.0K | 49.6K |
| BlackRock, Inc. | 62.0K | 45.3K |
| DIMENSIONAL FUND ADVISORS LP | 52.1K | 38.1K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-04 | — | on EDGAR ↗ |
| 8-K | 2026-08-03 | 2026-08-03 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-07-23 | — | on EDGAR ↗ |
| EFFECT | 2026-06-18 | — | on EDGAR ↗ |
| S-1 | 2026-06-12 | — | on EDGAR ↗ |
| 8-K | 2026-06-02 | 2026-06-01 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript · 2026-08-21
- Lantern Pharma GAAP EPS of -$0.57 misses by $0.19 · 2026-08-14
- Lantern Pharma Inc. (LTRN) filed form 8-K · 2026-08-14 · SEC EDGAR
- Lantern Pharma Inc. (LTRN) filed form 8-K · 2026-08-14 · SEC EDGAR
- Lantern Pharma Inc. (LTRN) filed form 10-Q · 2026-08-14 · SEC EDGAR
Ask the AI about LTRN
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →